Hype to HIGH IMPACT: AI ImplEMEntation From Discovery to Delivery
23 - 25 September 2025
| Amsterdam
The EU AI Act Explained: What Every Pharma Leader Needs to Know
The EU AI Act is not just a compliance issue — it’s a strategic point for every pharma and healthcare leader using AI.
With enforcement beginning in 2026, the Act classifies most healthcare AI systems — from clinical decision support tools to AI-powered medical devices — as “high-risk”, triggering new and intensive requirements: transparency, data integrity, human oversight, and continuous monitoring.
Download this deep-dive analysis to understand:
- What the EU AI Act really means for clinical trials, R&D, diagnostics, and digital health tools
- How high-risk AI will be regulated and why most pharma use cases fall into this category
- Why acting now creates a strategic edge, not just legal compliance
In Partnership With:
QUESTIONS?
Address: IQPC Ltd, 129 Wilton Road,
London SW1V 1JZ
Telephone: +44 (0) 1135 210 042
Fax: 44 (0) 207 368 9301
Email: enquire@iqpc.co.uk
©2025 IQPC. All rights reserved.
